Tuomo Pätsi has served on the Notable Board of Directors since 2023. He has more than 30 years of experience working in the biotech and pharmaceutical industries.
Since March 2022, Pätsi has served as an advisor to various biopharma companies and investors. Between July 2020 and February 2022, he served as the executive vice president of Seagen Inc. (Nasdaq: SGEN), a U.S.-based cancer-focused biotechnology company. Between November 2012 and June 2020, Pätsi served in various capacities at Celgene Corp., which was later acquired by Bristol-Myers Squibb Company (NYSE: BMY), including serving as the president of the EMEA region and worldwide markets and president of European and international operations, engaged primarily in the development and commercialization of therapies for the treatment of cancer. Pätsi participated in strategic deals and partnerships and co-led the international commercial integration of Celgene and Bristol-Myers Squibb Company. Prior to his work at Celgene, he served as vice president of Europe for Human Genome Science, and over a period of 11 years he served in roles of increasing responsibility at Amgen Inc., in Europe and the United States. Pätsi has served as board member of Aqsens Health since April 2023 and as a non-executive director of Faron Pharmaceuticals Ltd. (AIM London: FARN, Nasdaq Helsinki First North: FARON) since March 2023.
Pätsi is a registered pharmacist and earned a master of science in pharmacology from the School of Pharmacy, Helsinki University, Helsinki, Finland.
